NOGA Therapeutics

Company Overview

Snapshot

Founded in January 2020 by Noam Baumatz, NOGA Therapeutics operates with 1–10 employees. The company has secured funding across two rounds from two investors, including Lonza. NOGA Therapeutics is currently advancing its therapeutic pipeline, which includes DopaGene for Parkinson's disease, towards clinical trial stages.

Business overview

NOGA Therapeutics is a gene therapy company focused on developing transformative treatments for patients with severe and chronic illnesses. The company utilizes advanced lentiviral vector technology to reprogram blood stem cells, enabling targeted production of essential proteins within specific cells and tissues. NOGA’s therapeutic pipeline includes DopaGene for Parkinson’s disease, as well as treatments for X-linked Agammaglobulinemia (XLA), lysosomal storage diseases, and inflammatory bowel disease (IBD). The company operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development industries with its cell-based biological solutions.

Company Intelligence Q&A

What is NOGA Therapeutics' primary focus?

NOGA Therapeutics specializes in gene therapies, utilizing blood stem cell reprogramming to develop treatments for severe and chronic illnesses, including Parkinson's disease, X-linked Agammaglobulinemia (XLA), lysosomal storage diseases, and inflammatory bowel disease (IBD).

Who founded NOGA Therapeutics?

NOGA Therapeutics was co-founded by Noam Baumatz.

When was NOGA Therapeutics founded?

NOGA Therapeutics was founded in January 2020.

What is the current stage of NOGA Therapeutics' product development?

NOGA Therapeutics' products, such as BTK-001 and DopaGene, are currently in the Clinical Trial stage.

Which investors have participated in NOGA Therapeutics' funding rounds?

NOGA Therapeutics has received funding from investors including Lonza and PipelBiz.